Systems Biology: A Therapeutic Target for Tumor TherapyReport as inadecuate




Systems Biology: A Therapeutic Target for Tumor Therapy - Download this document for free, or read online. Document in PDF available to download.

Cancer Microenvironment

, 1:159

First Online: 23 July 2008Received: 28 April 2008Accepted: 26 June 2008DOI: 10.1007-s12307-008-0012-5

Cite this article as: Reichle, A. & Vogt, T. Cancer Microenvironment 2008 1: 159. doi:10.1007-s12307-008-0012-5

Abstract

Tumor-related activities that seem to be operationally induced by the division of function, such as inflammation, neoangiogenesis, Warburg effect, immune response, extracellular matrix remodeling, cell proliferation rate, apoptosis, coagulation effects, present itself from a systems perspective as an enhancement of complexity. We hypothesized, that tumor systems-directed therapies might have the capability to use aggregated action effects, as adjustable sizes to therapeutically modulate the tumor systems’ stability, homeostasis, and robustness. We performed a retrospective analysis of recently published data on 224 patients with advanced and heavily pre-treated 10% to 63% vascular sarcoma, melanoma, renal clear cell, cholangiocellular, carcinoma, hormone-refractory prostate cancer, and multivisceral Langerhans’ cell histiocytosis enrolled in nine multi-center phase II trials 11 centers. Each patient received a multi-targeted systems-directed therapy that consisted of metronomic low-dose chemotherapy, a COX-2 inhibitor, combined with one or two transcription modulators, pioglitazone +-− dexamethasone or IFN-alpha. These treatment schedules may attenuate the metastatic potential, tumor-associated inflammation, may exert site-specific activities, and induce long-term disease stabilization followed by prolonged objective response 3% to 48% despite poor monoactivity of the respective drugs. Progression-free survival data are comparable with those of reductionist-designed standard first-line therapies. The differential response patterns indicate the therapies’ systems biological activity. Understanding systems biology as adjustable size may break through the barrier of complex tumor-stroma-interactions in a therapeutically relevant way: Comparatively high efficacy at moderate toxicity. Structured systems-directed therapies in metastatic cancer may get a source for detecting the topology of tumor-associated complex aggregated action effects as adjustable sizes available for targeted biomodulatory therapies.

KeywordsSystems biology Tumor microenvironment Transcription factors Pioglitazone PPARs Dexamethasone Interferon-alpha COX-2 inhibitor Metronomic low dose chemotherapy  Download fulltext PDF



Author: Albrecht Reichle - Thomas Vogt

Source: https://link.springer.com/







Related documents